Paxlovid Accelerates COVID-19 Recovery but Fails to Lower Hospitalization Rates in Vaccinated Patients
Recent research into Paxlovid, an antiviral medication developed by Pfizer, indicates that while it speeds up recovery in high-risk COVID-19 patients, it does not significantly reduce hospital admissions among vaccinated individuals. This conclusion is based on findings from two open-label trials, the UK 'PANORAMIC' trial and the Canadian 'CanTreatCOVID' trial, involving over 4,200 participants. These trials included individuals aged 50 and above or younger individuals with conditions like diabetes or asthma. Participants were either given Paxlovid or received usual care, with the majority having been vaccinated against COVID-19. The trials showed that Paxlovid reduced the median recovery time significantly compared to usual care. However, the rate of hospitalization or death did not differ substantially between the Paxlovid group and the usual care group. 
